The Patent Finder

Coronavirus Vaccine Formulations

Novavax, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 7 of these applications claim priority to application 62/966,271, filed Jan 27, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 10,953,089Coronavirus Vaccine Formulations
In force
 · High confidence
UsedRemaining
Novavax Inc.In forceHigh confidence
US 11,253,586Coronavirus Vaccine Formulations
In force
 · High confidence
Novavax, Inc.In forceHigh confidence
US 11,541,112Coronavirus Vaccine Formulations
In force
 · High confidence
Novavax, Inc.In forceHigh confidence
US 11,896,664Coronavirus Vaccine Formulations
In force
 · Medium confidence
Novavax, Inc.In forceMedium confidence
US 12,472,246Coronavirus Vaccine Formulations
In force
 · Medium confidence
Novavax, Inc.In forceMedium confidence
US 12,491,241Coronavirus Vaccine Formulations
In force
 · High confidence
Novavax, Inc.In forceHigh confidence
US 12,691,171Coronavirus Vaccine Formulations
In force
 · High confidence
Novavax, Inc.In forceHigh confidence
Application 19/368,715Coronavirus Vaccine Formulations
Pending
Not granted
Novavax, Inc.PendingNot granted
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
7 of these are in force and held by Novavax, Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited